You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
A JAMA study found that low-value diagnostic tests are common in inpatient settings, and machine learning systems can be used to identify those tests and reduce their overutilization.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
While microbiology has traditionally relied heavily on manual processes, most workflows can now be automated, and AI tools promise to streamline it further.
The system is designed to analyze data from routine blood and biochemistry tests to identify immunological abnormalities that indicate high cancer risk.
Rutgers researchers have developed a point-of-care tool that can rapidly assess the sensitivity of tumor cells to cancer drugs without staining or labeling.
The researchers said that they have demonstrated an approach that skirts a bottleneck and enables building pathology support systems from large datasets.
Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
The new partnership also gives clinical Dx analytics firm Prognos access to Datavant's pharma and biotech customers.